Novo Nordisk A/S said on Friday that it will rebrand an existing oral semaglutide diabetes medication as Ozempic in the United States, with sales to begin on Monday. The renamed pill will be offered to adults in three strengths - 1.5 milligram, 4 mg and 9 mg - and distributed through a network of more than 70,000 pharmacies nationwide.
The company told investors and the market that the relaunched Ozempic tablets are as safe and effective as those currently sold under the Rybelsus name. Both products contain semaglutide as the principal active ingredient, although they differ in formulation and the specific dosing options available. Novo Nordisk said it will continue to market Rybelsus outside the United States.
Company executives framed the rebranding as part of a broader commercial strategy. The move comes amid an effort to reclaim sales volumes and market presence from Eli Lilly & Co., and follows a series of product and distribution initiatives by Novo Nordisk. Those initiatives include the introduction of a Wegovy tablet in January, which the company said recorded the strongest launch of any obesity medicine to date, and the rollout of a subscription program that offers lower monthly pricing for Wegovy.
In describing the relaunch, Novo Nordisk emphasized continuity of the active ingredient between the former Rybelsus tablets and the newly labeled Ozempic pills while noting the differences in formulation and dose range. The company has highlighted the expanded pharmacy reach for the Ozempic-branded tablets as a means of improving availability to adult patients across the US.
Observers will watch how the name change, expanded dosing lineup and pharmacy distribution affect competitive dynamics in the diabetes and obesity treatment markets. Novo Nordisk has signaled a parallel focus on developing new formulations and pursuing more direct-to-consumer marketing approaches as part of its effort to regain share from competitors.